145 related articles for article (PubMed ID: 31329831)
1. BarrettNET-a prospective registry for risk estimation of patients with Barrett's esophagus to progress to adenocarcinoma.
Wiethaler M; Slotta-Huspenina J; Brandtner A; Horstmann J; Wein F; Baumeister T; Radani N; Gerland S; Anand A; Lange S; Schmidt M; Janssen KP; Conrad A; Johannes W; Strauch K; Quante AS; Linkohr B; Kuhn KA; Blaser R; Lehmann A; Kohlmayer F; Weichert W; Schmid RM; Becker KF; Quante M
Dis Esophagus; 2019 Aug; 32(8):. PubMed ID: 31329831
[TBL] [Abstract][Full Text] [Related]
2. Epidemiologic Risk Factors in a Comparison of a Barrett Esophagus Registry (BarrettNET) and a Case-Control Population in Germany.
Schmidt M; Ankerst DP; Chen Y; Wiethaler M; Slotta-Huspenina J; Becker KF; Horstmann J; Kohlmayer F; Lehmann A; Linkohr B; Strauch K; Schmid RM; Quante AS; Quante M
Cancer Prev Res (Phila); 2020 Apr; 13(4):377-384. PubMed ID: 32066580
[TBL] [Abstract][Full Text] [Related]
3. [Screening for adenocarcinoma in Barrett's esophagus: yes or no, when and how?].
Sostres C; Lacarta P; Lanas A
Gastroenterol Hepatol; 2013 Oct; 36(8):520-6. PubMed ID: 23453559
[TBL] [Abstract][Full Text] [Related]
4. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
5. A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.
Duits LC; Lao-Sirieix P; Wolf WA; O'Donovan M; Galeano-Dalmau N; Meijer SL; Offerhaus GJA; Redman J; Crawte J; Zeki S; Pouw RE; Chak A; Shaheen NJ; Bergman JJGHM; Fitzgerald RC
Dis Esophagus; 2019 Jan; 32(1):. PubMed ID: 30496496
[TBL] [Abstract][Full Text] [Related]
6. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
[TBL] [Abstract][Full Text] [Related]
8. Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus.
Thota PN; Kistangari G; Singh P; Cummings L; Hajifathalian K; Lopez R; Sanaka MR
Dig Dis Sci; 2016 Jan; 61(1):247-54. PubMed ID: 26233550
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
10. Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?
Inadomi JM; Saxena N
Dig Dis Sci; 2018 Aug; 63(8):2094-2104. PubMed ID: 29948571
[TBL] [Abstract][Full Text] [Related]
11. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
[TBL] [Abstract][Full Text] [Related]
12. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
13. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
14. Incidence of adenocarcinoma among patients with Barrett's esophagus.
Hvid-Jensen F; Pedersen L; Drewes AM; Sørensen HT; Funch-Jensen P
N Engl J Med; 2011 Oct; 365(15):1375-83. PubMed ID: 21995385
[TBL] [Abstract][Full Text] [Related]
15. Screening and surveillance for Barrett's esophagus: current issues and future directions.
Choi SE; Hur C
Curr Opin Gastroenterol; 2012 Jul; 28(4):377-81. PubMed ID: 22508325
[TBL] [Abstract][Full Text] [Related]
16. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
17. A Barrett's esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia.
Picardo SL; O'Brien MP; Feighery R; O'Toole D; Ravi N; O'Farrell NJ; O'Sullivan JN; Reynolds JV
Dis Esophagus; 2015; 28(2):121-6. PubMed ID: 24428806
[TBL] [Abstract][Full Text] [Related]
18. Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.).
Thota PN; Arora Z; Benjamin T; Pagadala M; Lopez R; Sanaka MR
Scand J Gastroenterol; 2016 Nov; 51(11):1288-93. PubMed ID: 27460942
[TBL] [Abstract][Full Text] [Related]
19. Barrett's Esophagus and esophageal adenocarcinoma.
Bresalier RS
Annu Rev Med; 2009; 60():221-31. PubMed ID: 18783330
[TBL] [Abstract][Full Text] [Related]
20. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
